Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA.

Ann Oncol. 2019 May 2. pii: mdz135. doi: 10.1093/annonc/mdz135. [Epub ahead of print]

PMID:
31046082
2.

Integrated Assessment of Wastewater Reuse, Exposure Risk, and Fish Endocrine Disruption in the Shenandoah River Watershed.

Barber LB, Rapp JL, Kandel C, Keefe SH, Rice J, Westerhoff P, Bertolatus DW, Vajda AM.

Environ Sci Technol. 2019 Apr 2;53(7):3429-3440. doi: 10.1021/acs.est.8b05655. Epub 2019 Mar 19.

PMID:
30888795
3.

Behavior of major and trace elements in a transient surface water/groundwater system following removal of a long-term wastewater treatment facility source.

Keefe SH, Barber LB, Hubbard LE, Bradley PM, Roth DA, Kolpin DW.

Sci Total Environ. 2019 Jun 10;668:867-880. doi: 10.1016/j.scitotenv.2019.02.358. Epub 2019 Feb 25.

PMID:
30870754
4.

Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.

Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS.

Brain. 2019 Apr 1;142(4):1063-1076. doi: 10.1093/brain/awz019.

PMID:
30753379
5.

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.

PMID:
29992241
6.

The Safer Futures Model: Developing Partnerships between Intimate Partner Violence and Health Care Agencies.

Kimball E, Rockhill A, Heyen C, Keefe SH.

Health Soc Work. 2018 Aug 1;43(3):201-204. doi: 10.1093/hsw/hly019. No abstract available.

PMID:
29893944
7.

Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.

Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B.

Circ Heart Fail. 2018 Mar;11(3):e004408. doi: 10.1161/CIRCHEARTFAILURE.117.004408.

8.

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J.

Lancet Oncol. 2017 Nov;18(11):1483-1492. doi: 10.1016/S1470-2045(17)30616-2. Epub 2017 Sep 26.

PMID:
28967485
9.

Effects of an Extreme Flood on Trace Elements in River Water-From Urban Stream to Major River Basin.

Barber LB, Paschke SS, Battaglin WA, Douville C, Fitzgerald KC, Keefe SH, Roth DA, Vajda AM.

Environ Sci Technol. 2017 Sep 19;51(18):10344-10356. doi: 10.1021/acs.est.7b01767. Epub 2017 Sep 1.

PMID:
28862461
10.

SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.

Fishbein L, Ben-Maimon S, Keefe S, Cengel K, Pryma DA, Loaiza-Bonilla A, Fraker DL, Nathanson KL, Cohen DL.

Endocr Relat Cancer. 2017 Aug;24(8):L51-L55. doi: 10.1530/ERC-17-0086. Epub 2017 May 31. No abstract available.

PMID:
28566531
11.

Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.

Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan D, Ky B.

Clin Cancer Res. 2017 Jul 15;23(14):3601-3609. doi: 10.1158/1078-0432.CCR-16-2869. Epub 2017 Feb 14.

12.

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

Weber JS, Levit LA, Adamson PC, Bruinooge SS, Burris HA 3rd, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.

J Clin Oncol. 2017 Jan 10;35(2):139-140. Epub 2016 Nov 28. No abstract available. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):357.

13.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.

14.

Innovation in Bladder Cancer Immunotherapy.

Grossman HB, Lamm DL, Kamat AM, Keefe S, Taylor JA 3rd, Ingersoll MA.

J Immunother. 2016 Oct;39(8):291-7. doi: 10.1097/CJI.0000000000000130. Review.

PMID:
27428265
15.

Pre/post-closure assessment of groundwater pharmaceutical fate in a wastewater-facility-impacted stream reach.

Bradley PM, Barber LB, Clark JM, Duris JW, Foreman WT, Furlong ET, Givens CE, Hubbard LE, Hutchinson KJ, Journey CA, Keefe SH, Kolpin DW.

Sci Total Environ. 2016 Oct 15;568:916-925. doi: 10.1016/j.scitotenv.2016.06.104. Epub 2016 Jun 24.

PMID:
27350092
16.

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

Narayan V, Mamtani R, Keefe S, Guzzo T, Malkowicz SB, Vaughn DJ.

Cancer Res Treat. 2016 Jul;48(3):1084-91. doi: 10.4143/crt.2015.405. Epub 2015 Dec 2.

17.

No Ceiling Dose: Effective Pain Control with Extraordinary Opiate Dosing in Cancer.

Varilla V, Schneiderman H, Keefe S.

Conn Med. 2015 Oct;79(9):521-4.

PMID:
26630702
18.

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.

Aspinall SL, Good CB, Zhao X, Cunningham FE, Heron BB, Geraci M, Passero V, Stone RA, Smith KJ, Rogers R, Shields J, Sartore M, Boyle DP, Giberti S, Szymanski J, Smith D, Ha A, Sessions J, Depcinski S, Fishco S, Molina I, Lepir T, Jean C, Cruz-Diaz L, Motta J, Calderon-Vargas R, Maland J, Keefe S, Tague M, Leone A, Glovack B, Kaplan B, Cosgriff S, Kaster L, Tonnu-Mihara I, Nguyen K, Carmichael J, Clifford L, Lu K, Chatta G.

BMC Cancer. 2015 Feb 18;15:62. doi: 10.1186/s12885-015-1038-y.

19.

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM.

Cancer Manag Res. 2015 Feb 11;7:65-73. doi: 10.2147/CMAR.S74202. eCollection 2015. Review.

20.

An Electronic Chemotherapy Ordering Process and Template.

Keefe S, Kambhampati S, Powers B.

Fed Pract. 2015 Jan;32(Suppl 1):21S-25S.

21.

Capitalizing on VA Best Practices.

Keefe S.

Fed Pract. 2015 Jan;32(Suppl 1):15S. No abstract available.

22.

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

Weber JS, Levit LA, Adamson PC, Bruinooge S, Burris HA 4th, Carducci MA, Dicker AP, Gönen M, Keefe SM, Postow MA, Thompson MA, Waterhouse DM, Weiner SL, Schuchter LM.

J Clin Oncol. 2015 Jan 20;33(3):278-84. doi: 10.1200/JCO.2014.58.2635. Epub 2014 Dec 15. No abstract available. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):353.

23.

Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database.

Mamtani R, Haynes K, Boursi B, Scott FI, Goldberg DS, Keefe SM, Vaughn DJ, Malkowicz SB, Lewis JD.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):303-7. doi: 10.1158/1055-9965.EPI-14-0677. Epub 2014 Nov 11.

24.

Riverbank filtration potential of pharmaceuticals in a wastewater-impacted stream.

Bradley PM, Barber LB, Duris JW, Foreman WT, Furlong ET, Hubbard LE, Hutchinson KJ, Keefe SH, Kolpin DW.

Environ Pollut. 2014 Oct;193:173-180. doi: 10.1016/j.envpol.2014.06.028. Epub 2014 Jul 16.

25.

Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study.

Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF.

Cancer Biol Ther. 2014 Jun 1;15(6):683-7. doi: 10.4161/cbt.28412. Epub 2014 Mar 11.

26.

Management of sorafenib-related adverse events: a clinician's perspective.

Brose MS, Frenette CT, Keefe SM, Stein SM.

Semin Oncol. 2014 Feb;41 Suppl 2:S1-S16. doi: 10.1053/j.seminoncol.2014.01.001. Epub 2014 Jan 9.

27.

Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD.

Diabetes Care. 2014 Jul;37(7):1910-7. doi: 10.2337/dc13-1489. Epub 2014 Feb 4.

28.

Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation.

Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn D, Keefe SM, Guzzo T, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):603-10. doi: 10.1016/j.ijrobp.2013.11.211. Epub 2014 Jan 7.

PMID:
24411628
29.

The molecular biology of renal cell carcinoma.

Keefe SM, Nathanson KL, Rathmell WK.

Semin Oncol. 2013 Aug;40(4):421-8. doi: 10.1053/j.seminoncol.2013.05.006. Review.

PMID:
23972705
30.

Persistence and potential effects of complex organic contaminant mixtures in wastewater-impacted streams.

Barber LB, Keefe SH, Brown GK, Furlong ET, Gray JL, Kolpin DW, Meyer MT, Sandstrom MW, Zaugg SD.

Environ Sci Technol. 2013 Mar 5;47(5):2177-88. doi: 10.1021/es303720g. Epub 2013 Feb 11.

PMID:
23398602
31.

Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.

Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ.

BJU Int. 2013 Jul;112(1):13-25. doi: 10.1111/j.1464-410X.2012.11762.x. Epub 2013 Jan 29. Review.

32.

MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.

Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA.

AJR Am J Roentgenol. 2013 Jan;200(1):120-6. doi: 10.2214/AJR.12.8536.

PMID:
23255750
33.

Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.

Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, Deville C, Bekelman JE, Tucker K, Hwang WT, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):363-9. doi: 10.1016/j.ijrobp.2012.03.061. Epub 2012 May 30.

PMID:
22658217
34.

A Web-based archive of systematic review data.

Ip S, Hadar N, Keefe S, Parkin C, Iovin R, Balk EM, Lau J.

Syst Rev. 2012 Feb 21;1:15. doi: 10.1186/2046-4053-1-15.

35.

A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.

Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang WT, Vaughn DJ, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):81-8. doi: 10.1016/j.ijrobp.2012.03.007. Epub 2012 Apr 28.

PMID:
22543204
36.

Fate of 4-nonylphenol and 17β-estradiol in the Redwood River of Minnesota.

Writer JH, Ryan JN, Keefe SH, Barber LB.

Environ Sci Technol. 2012 Jan 17;46(2):860-8. doi: 10.1021/es2031664. Epub 2011 Dec 30.

PMID:
22208914
37.

Air pollution is associated with brainstem auditory nuclei pathology and delayed brainstem auditory evoked potentials.

Calderón-Garcidueñas L, D'Angiulli A, Kulesza RJ, Torres-Jardón R, Osnaya N, Romero L, Keefe S, Herritt L, Brooks DM, Avila-Ramirez J, Delgado-Chávez R, Medina-Cortina H, González-González LO.

Int J Dev Neurosci. 2011 Jun;29(4):365-75. doi: 10.1016/j.ijdevneu.2011.03.007. Epub 2011 Mar 31.

38.

Lagrangian mass-flow investigations of inorganic contaminants in wastewater-impacted streams.

Barber LB, Antweiler RC, Flynn JL, Keefe SH, Kolpin DW, Roth DA, Schnoebelen DJ, Taylor HE, Verplanck PL.

Environ Sci Technol. 2011 Apr 1;45(7):2575-83. doi: 10.1021/es104138y. Epub 2011 Mar 7.

PMID:
21381683
39.

Lung cancer management in 2010.

Ganti AK, Huang CH, Klein MA, Keefe S, Kelley MJ.

Oncology (Williston Park). 2011 Jan;25(1):64-73. Review.

40.

Urban air pollution produces up-regulation of myocardial inflammatory genes and dark chocolate provides cardioprotection.

Villarreal-Calderon R, Reed W, Palacios-Moreno J, Keefe S, Herritt L, Brooks D, Torres-Jardón R, Calderón-Garcidueñas L.

Exp Toxicol Pathol. 2012 May;64(4):297-306. doi: 10.1016/j.etp.2010.09.002. Epub 2010 Oct 6.

41.

The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer.

Keefe SM, Demichele A.

Curr Oncol Rep. 2010 Jan;12(1):22-5. doi: 10.1007/s11912-009-0080-9. Review.

PMID:
20425604
42.

Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.

Keefe SM, Cohen MA, Brose MS.

Clin Cancer Res. 2010 Feb 1;16(3):778-83. doi: 10.1158/1078-0432.CCR-08-2743. Epub 2010 Jan 26. Review.

43.

On the importance of heterogeneity in meta-analysis.

Keefe SM, Strom BL.

Clin Trials. 2009 Oct;6(5):443-4; discussion 445. doi: 10.1177/1740774509344372. No abstract available.

PMID:
19846896
44.

Fate of sulfamethoxazole, 4-nonylphenol, and 17beta-estradiol in groundwater contaminated by wastewater treatment plant effluent.

Barber LB, Keefe SH, Leblanc DR, Bradley PM, Chapelle FH, Meyer MT, Loftin KA, Kolpin DW, Rubio F.

Environ Sci Technol. 2009 Jul 1;43(13):4843-50.

PMID:
19673274
45.

Urban air pollution: influences on olfactory function and pathology in exposed children and young adults.

Calderón-Garcidueñas L, Franco-Lira M, Henríquez-Roldán C, Osnaya N, González-Maciel A, Reynoso-Robles R, Villarreal-Calderon R, Herritt L, Brooks D, Keefe S, Palacios-Moreno J, Villarreal-Calderon R, Torres-Jardón R, Medina-Cortina H, Delgado-Chávez R, Aiello-Mora M, Maronpot RR, Doty RL.

Exp Toxicol Pathol. 2010 Jan;62(1):91-102. doi: 10.1016/j.etp.2009.02.117. Epub 2009 Mar 17.

46.

Childhood ALL and second neoplasms.

Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS.

Cancer Biol Ther. 2007 Oct;6(10):1525-31. Epub 2007 Aug 23. Review.

PMID:
17952026
47.

Long-term natural attenuation of carbon and nitrogen within a groundwater plume after removal of the treated wastewater source.

Repert DA, Barber LB, Hess KM, Keefe SH, Kent DB, LeBlanc DR, Smith RL.

Environ Sci Technol. 2006 Feb 15;40(4):1154-62.

PMID:
16572769
48.

Accumulation of contaminants in fish from wastewater treatment wetlands.

Barber LB, Keefe SH, Antweiler RC, Taylor HE, Wass RD.

Environ Sci Technol. 2006 Jan 15;40(2):603-11.

PMID:
16468409
49.

Fate of volatile organic compounds in constructed wastewater treatment wetlands.

Keefe SH, Barber LB, Runkel RL, Ryan JN.

Environ Sci Technol. 2004 Apr 1;38(7):2209-16.

PMID:
15112826
50.

Sensory integration dysfunction. Recognition in primary care settings.

Keefe S.

Adv Nurse Pract. 2004 Jan;12(1):57-8. Review. No abstract available.

PMID:
14730839

Supplemental Content

Support Center